Trial deaths frustrate Merck's bid to pair Keytruda with Celgene's myeloma stars
admin 6th July 2017 Uncategorised 0After reviewing deaths in two Keytruda trials, the FDA put both Merck studies on clinical hold and stopped Keytruda dosing in a third, thwarting Merck’s hopes for combining Keytruda with Celgene’s big-selling myeloma meds Pomalyst and Revlimid.
More: Trial deaths frustrate Merck's bid to pair Keytruda with Celgene's myeloma stars
Source: fierce